Simon Pahnke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon Pahnke has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Hahn
Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
8 shared publications - Anders Sundin
Department of Surgical Sciences, Radiology and Molecular Imaging Uppsala University Uppsala Sweden
8 shared publications - Angelica Loskog
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
8 shared publications - Clara Nordström
Lokon Pharma AB, Uppsala, Sweden
8 shared publications - Emma Eriksson
Uppsala University 1 Department of Immunology, Genetics and Pathology Uppsala, Sweden
8 shared publications - Gustav J. Ullenhag
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
8 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 131, e14245
Immune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023
Background: The introduction of immune checkpoint inhibitor (ICI) treatment has significantly improved the treatment of several cancer diagnoses, such as non-small cell lung cancer, renal and urothelial carcinoma, melanoma. However, there is a lack of real-world data on ICI treatment and outcomes from the Swedish healthcare setting. The cost of treatment is also significant, and securing equal access to emerging drugs for all patients is challenging in an era of rapidly evolving treatment recommendations. Methods: We conducted a population-based observational study of incident cases among ICI-treated patients, using a novel electronic healthcare record source for systemic cancer drugs linked to regional and national register data. Overall survival (OS) was calculated from start of the first ICI-treatment, using the Kaplan-Meier method. The aim was to examine treatment with ICI drugs during 2015–2023 in 10 Swedish regions (total population 4.3 million). Results: Median real-world OS was 2.0 years (95% confidence interval: 1.8–2.2 years) from start of ICI-treatment for patients with known palliative treatment intent (n = 1,941, lung 2.2 years, melanoma 5.0 years, renal 2.3 years, urothelial 1.1 years, head/neck 1.4 years). In 2023, 6.7% of all patients receiving systemic antineoplastic treatment for cancer were treated with ICI (74 per 100,000 inhabitants). The timing of the adoption of treatment with ICI drugs and the current patterns of use differed between Swedish regions. Conclusion: This study provides the first Swedish real-world OS estimates after ICI-treatment across major diagnoses, documents the rapidly increasing ICI use, and describes regional variation in treatment patterns.
- 12 August 2026
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 131, e14245
Open AccessImmune checkpoint inhibitor treatment – real-world use and outcomes in Sweden 2015–2023
Background: The introduction of immune checkpoint inhibitor (ICI) treatment has significantly improved the treatment of several cancer diagnoses, such as non-small cell lung cancer, renal and urothelial carcinoma, melanoma. However, there is a lack of real-world data on ICI treatment and outcomes from the Swedish healthcare setting. The cost of treatment is also significant, and securing equal access to emerging drugs for all patients is challenging in an era of rapidly evolving treatment recommendations. Methods: We conducted a population-based observational study of incident cases among ICI-treated patients, using a novel electronic healthcare record source for systemic cancer drugs linked to regional and national register data. Overall survival (OS) was calculated from start of the first ICI-treatment, using the Kaplan-Meier method. The aim was to examine treatment with ICI drugs during 2015–2023 in 10 Swedish regions (total population 4.3 million). Results: Median real-world OS was 2.0 years (95% confidence interval: 1.8–2.2 years) from start of ICI-treatment for patients with known palliative treatment intent (n = 1,941, lung 2.2 years, melanoma 5.0 years, renal 2.3 years, urothelial 1.1 years, head/neck 1.4 years). In 2023, 6.7% of all patients receiving systemic antineoplastic treatment for cancer were treated with ICI (74 per 100,000 inhabitants). The timing of the adoption of treatment with ICI drugs and the current patterns of use differed between Swedish regions. Conclusion: This study provides the first Swedish real-world OS estimates after ICI-treatment across major diagnoses, documents the rapidly increasing ICI use, and describes regional variation in treatment patterns.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Figure S1. Consort diagram and study timeline.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Figure S1. Consort diagram and study timeline.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S3. Significantly changed biomarkers in tumor biopsies using Nanostring.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S3. Significantly changed biomarkers in tumor biopsies using Nanostring.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S2. Adverse events and serious adverse events independently of attribution.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S2. Adverse events and serious adverse events independently of attribution.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Figure S2. Anti-drug antibodies.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Figure S2. Anti-drug antibodies.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S1. Representativeness of Study Participants.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Supplementary Table S1. Representativeness of Study Participants.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Purpose:Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In this study, tolerability (primary endpoint), response activity, and the capacity to inflame the TME were evaluated. Patients and Methods:In an open-label, single-arm phase I/IIb clinical trial (NCT03225989), a maximum of eight intratumoral injections of LOAd703 were administered biweekly, combined with a gemcitabine-based chemotherapy regimen, either standard-of-care treatment or conditioning gemcitabine if no standard options were available. Dose escalation followed a standard 3 + 3 design (phase I) and, to optimize dosage, the two highest dose levels were expanded in phase II. Results:Forty-one patients were enrolled with pancreatic (n = 29), colorectal (n = 5), ovarian (n = 4), and biliary cancers (n = 3). Treatment was generally well tolerated. The most common LOAd703-related adverse events were pyrexia (76%), chills (39%), and fatigue (34%), mostly grade 1 to 2. The overall response rate (ORR) was 0 in the LOAd703 dose cohort 5 × 1010 viral particles (VP), 25% in 1 × 1011 VP, and 12% in 5 × 1011 VP. All patients with an objective response had pancreatic cancer and received first-line treatment (ORR, 35%). The TME showed a significant upregulation of Th1 immunity biomarkers at week 13 posttreatment initiation. Conclusions:TME gene engineering using LOAd703 inflamed immune cold tumors and was followed by long-term stabilized disease in several patients. Further evaluation of LOAd703 together with chemotherapy and/or checkpoint inhibitors is warranted.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Purpose:Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In this study, tolerability (primary endpoint), response activity, and the capacity to inflame the TME were evaluated. Patients and Methods:In an open-label, single-arm phase I/IIb clinical trial (NCT03225989), a maximum of eight intratumoral injections of LOAd703 were administered biweekly, combined with a gemcitabine-based chemotherapy regimen, either standard-of-care treatment or conditioning gemcitabine if no standard options were available. Dose escalation followed a standard 3 + 3 design (phase I) and, to optimize dosage, the two highest dose levels were expanded in phase II. Results:Forty-one patients were enrolled with pancreatic (n = 29), colorectal (n = 5), ovarian (n = 4), and biliary cancers (n = 3). Treatment was generally well tolerated. The most common LOAd703-related adverse events were pyrexia (76%), chills (39%), and fatigue (34%), mostly grade 1 to 2. The overall response rate (ORR) was 0 in the LOAd703 dose cohort 5 × 1010 viral particles (VP), 25% in 1 × 1011 VP, and 12% in 5 × 1011 VP. All patients with an objective response had pancreatic cancer and received first-line treatment (ORR, 35%). The TME showed a significant upregulation of Th1 immunity biomarkers at week 13 posttreatment initiation. Conclusions:TME gene engineering using LOAd703 inflamed immune cold tumors and was followed by long-term stabilized disease in several patients. Further evaluation of LOAd703 together with chemotherapy and/or checkpoint inhibitors is warranted.
- 30 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1263-1265
The risk of anxiety and depression in Swedish potential stem cell donors—need for increased psychological evaluation and support?
- 30 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1263-1265
The risk of anxiety and depression in Swedish potential stem cell donors—need for increased psychological evaluation and support?
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF12
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Purpose: Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In this study, tolerability (primary endpoint), response activity, and the capacity to inflame the TME were evaluated. Patients and Methods: In an open-label, single-arm phase I/IIb clinical trial (NCT03225989), a maximum of eight intratumoral injections of LOAd703 were administered biweekly, combined with a gemcitabine-based chemotherapy regimen, either standard-of-care treatment or conditioning gemcitabine if no standard options were available. Dose escalation followed a standard 3 + 3 design (phase I) and, to optimize dosage, the two highest dose levels were expanded in phase II. Results: Forty-one patients were enrolled with pancreatic (n = 29), colorectal (n = 5), ovarian (n = 4), and biliary cancers (n = 3). Treatment was generally well tolerated. The most common LOAd703-related adverse events were pyrexia (76%), chills (39%), and fatigue (34%), mostly grade 1 to 2. The overall response rate (ORR) was 0 in the LOAd703 dose cohort 5 × 1010 viral particles (VP), 25% in 1 × 1011 VP, and 12% in 5 × 1011 VP. All patients with an objective response had pancreatic cancer and received first-line treatment (ORR, 35%). The TME showed a significant upregulation of Th1 immunity biomarkers at week 13 posttreatment initiation. Conclusions: TME gene engineering using LOAd703 inflamed immune cold tumors and was followed by long-term stabilized disease in several patients. Further evaluation of LOAd703 together with chemotherapy and/or checkpoint inhibitors is warranted.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF12
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial
Purpose: Patients with advanced cancer have a poor prognosis and need for novel treatments. LOAd703 is a tumor microenvironment (TME) gene engineering viral vector encoding genes targeting the CD40 and 4-1BB pathways. In this study, tolerability (primary endpoint), response activity, and the capacity to inflame the TME were evaluated. Patients and Methods: In an open-label, single-arm phase I/IIb clinical trial (NCT03225989), a maximum of eight intratumoral injections of LOAd703 were administered biweekly, combined with a gemcitabine-based chemotherapy regimen, either standard-of-care treatment or conditioning gemcitabine if no standard options were available. Dose escalation followed a standard 3 + 3 design (phase I) and, to optimize dosage, the two highest dose levels were expanded in phase II. Results: Forty-one patients were enrolled with pancreatic (n = 29), colorectal (n = 5), ovarian (n = 4), and biliary cancers (n = 3). Treatment was generally well tolerated. The most common LOAd703-related adverse events were pyrexia (76%), chills (39%), and fatigue (34%), mostly grade 1 to 2. The overall response rate (ORR) was 0 in the LOAd703 dose cohort 5 × 1010 viral particles (VP), 25% in 1 × 1011 VP, and 12% in 5 × 1011 VP. All patients with an objective response had pancreatic cancer and received first-line treatment (ORR, 35%). The TME showed a significant upregulation of Th1 immunity biomarkers at week 13 posttreatment initiation. Conclusions: TME gene engineering using LOAd703 inflamed immune cold tumors and was followed by long-term stabilized disease in several patients. Further evaluation of LOAd703 together with chemotherapy and/or checkpoint inhibitors is warranted.